Statistik Asas
| CIK | 1504389 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rich Pharmaceuticals Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| July 6, 2021 |
8-K 1 rcha8k.htm 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2021 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) WYOMING 000-54767 46-3259117 (State or other jurisdiction of incorporation) (Comm |
|
| July 3, 2019 |
Asset Assignment Agreement dated June 11, 2019 with Richard L. Chang Holdings LLC EX-10.74 2 ex1074.htm EX-10.74 ASSET ASSIGNMENT AGREEMENT This Asset Assignment Agreement (“Agreement”) is entered into as of June 11, 2019 (the “Effective Date”) by and among Richard L. Chang Holding's, LLC, a Nevada limited liability company (“Holdings LLC”), and Rich Pharmaceuticals, Inc. a Wyoming corporation (“RICH”). Whereas, Holdings has previously assigned the Patent Assets (as defined bel |
|
| July 3, 2019 |
Promissory Note dated June 19, 2019 with SD Law Group APC EX-10.77 5 ex1077.htm EX-10.77 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STA |
|
| July 3, 2019 |
Asset Licensing Agreement dated June 11, 2019 with Geopulse Exploration, Inc. ASSET LICENSING AGREEMENT This Asset Assignment Agreement (“Agreement”) is entered into as of June 11, 2019 (the “Effective Date”) by and among Rich Pharmaceuticals Inc. |
|
| July 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2019 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) WYOMING 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| July 3, 2019 |
Promissory Note dated June 19, 2019 with Richard L. Chang Holdings LLC NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| March 19, 2019 |
RCHA / Rich Pharmaceuticals, Inc. RW RICH PHARMACEUTICALS, INC. 9595 Wilshire Blvd, Suite 900 Beverly Hills, CA 90212 March 14, 2019 SECURITIES AND EXCHANGE COMMISSION 100 F. Street NE Washington, D.C. 20549 Re: Rich Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-222677 Application for Withdrawal Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as amended, Rich Pharmaceuticals, Inc. |
|
| February 12, 2019 |
RICH PHARMACEUTICALS, INC. 2019 STOCK OPTION/STOCK ISSUANCE PLAN Article One GENERAL PROVISIONS RICH PHARMACEUTICALS, INC. 2019 STOCK OPTION/STOCK ISSUANCE PLAN Article One GENERAL PROVISIONS I. PURPOSE OF THE PLAN This 2019 Stock Option/Stock Issuance Plan is intended to promote the interests of Rich Pharmaceuticals, Inc., a Wyoming corporation (the “Corporation”), by providing eligible persons with the opportunity to acquire a proprietary interest, or otherwise increase their proprietary i |
|
| February 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2019 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) WYOMING 000-54767 46-3259117 (State or other jurisdiction of incorporation or organ |
|
| July 17, 2018 |
____________________________ RICH PHARMACEUTICALS, INC. ARTICLE I — OFFICES BYLAWS OF RICH PHARMACEUTICALS, INC. ARTICLE I — OFFICES Section 1.1 Principal Office. The principal office and place of business of Rich Pharmaceuticals, Inc. (the “Corporation”) shall be at such location as may be determined from time to time by the Board of Directors of the Corporation. Section 1.2 Other Offices. Other offices and places of business either within or without the State of Wyoming |
|
| July 17, 2018 |
PLAN OF CONVERSION OF Rich Pharmaceuticals, Inc., A NEVADA CORPORATION TO Rich Pharmaceuticals, Inc., A WYOMING CORPORATION THIS PLAN OF CONVERSION, dated as of February 28, 2018 (including all of the Exhibits attached hereto, this “Plan”), is hereby adopted by Rich Pharmaceuticals, Inc., a Nevada corporation (the “Company”), in order to set forth the terms, conditions and procedures governing the |
|
| July 17, 2018 |
Articles of Incorporation--Wyoming ARTICLES OF INCORPORATION OF Rich Pharmaceuticals, Inc. ARTICLE I NAME The name of the corporation shall be Rich Pharmaceuticals, Inc. (hereinafter, the “Corporation”). ARTICLE II REGISTERED OFFICE The initial office of the Corporation shall be 9595 Wilshire Blvd, Suite 900 Beverly Hills, CA 90212. The initial registered agent of the Corporation shall be Buffalo Registered Agents LLC at 412 N Main |
|
| July 17, 2018 |
RCHA / Rich Pharmaceuticals, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-54146 RICH PHARMACEUTICALS, INC. (Exact name of re |
|
| July 17, 2018 |
Articles of Domestication--Wyoming ARTICLES OF DOMESTICATION OF RICH PHARMACEUTICALS, INC. Pursuant to W.S. 17-16-1801 of the Wyoming Business Corporation Act, the undersigned hereby applies for a Certificate of Domestication and for that purpose hereby submits Articles of Domestication. 1. Existing Corporate Name. The name of the Company is Rich Pharmaceuticals, Inc. 2. Jurisdiction of Incorporation. The Company was incorporated u |
|
| July 2, 2018 |
RCHA / Rich Pharmaceuticals, Inc. NT 10-K NT 10-K 1 rchant10k.htm NT 10-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 0001504389 Notification of Late Filing (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: March 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Tran |
|
| April 13, 2018 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2018 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| March 23, 2018 |
Promissory Note dated March 15, 2018 in favor of GHS Investments, LLC NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| March 23, 2018 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2018 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| March 23, 2018 |
Securities Purchase Agreement dated March 15, 2018 with GHS Investments, LLC SECURITIES PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (“Agreement”) is made as of the 15th day of March, 2018 by and between Rich Pharmaceuticals, Inc. |
|
| March 15, 2018 |
RCHA / Rich Pharmaceuticals, Inc. DEF 14C SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 9, 2018 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2018 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| March 2, 2018 |
RCHA / Rich Pharmaceuticals, Inc. PRE 14C PRE 14C 1 rchapre14c.htm PRE 14C SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No.) Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(21)) [ ] Definitive Information Statement Rich Pharmaceuticals, Inc. (Name of Registrant as Sp |
|
| February 26, 2018 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2018 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| February 20, 2018 |
RCHA / Rich Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2017 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number: 000-54767 Rich Pharmaceuticals, Inc. |
|
| February 15, 2018 |
RCHA / Rich Pharmaceuticals, Inc. NT 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54767 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] |
|
| February 6, 2018 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2018 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| January 24, 2018 |
RCHA / Rich Pharmaceuticals, Inc. RW RICH PHARMACEUTICALS, INC. 9595 Wilshire Blvd, Suite 900 Beverly Hills, CA 90212 January 24, 2018 SECURITIES AND EXCHANGE COMMISSION 100 F. Street NE Washington, D.C. 20549 Re: Rich Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-217307 Application for Withdrawal Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as amended, Rich Pharmaceuticals, Inc |
|
| January 24, 2018 |
Certificate of Amendment to Certificate of Designation, dated February 3, 2017 BARBARA K. CEGAVSKE Secretary of State 206 North Carson Street Carson City, Nevada 89701-4299 (775) 684 5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class of Series (PURSUANT TO NRS 78.1955) Filed in the office of Barbara K. Cegavske Secretary of State State of Nevada Document Number 20170054030-63 Filing Date and Time 02/03/2017 7:38 AM Entity Number E0385 |
|
| January 24, 2018 |
As filed with the Securities and Exchange Commission on January 24, 2018 Registration No. |
|
| January 24, 2018 |
BARBARA K. CEGAVSKE Secretary of State 206 North Carson Street Carson City, Nevada 89701-4299 (775) 684 5708 Website: secretaryofstate.biz Certificate of Change Pursuant to NRS 78.209 Filed in the office of Ross Miller Secretary of State State of Nevada Document Number 20170207361-19 Filing Date and Time 05/10/2017 8:21 AM Entity Number E0385202010-4 ABOVE SPACE IS FOR OFFICE USE ONLY USE BLACK IN |
|
| January 24, 2018 |
Amendment to Articles of Incorporation, dated March 30, 2017 BARBARA K. CEGAVSKE Secretary of State 206 North Carson Street Carson City, Nevada 89701-4299 (775) 684 5708 Website: secretaryofstate.biz Certificate of Amendment (PURSUANT TO NRS 78.385 and 78.390) USE BLACK INK ONLY-DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Articles of Incorporation For Nevada Corporations (Pursuant to NRS 78.385 and 78.390?After Issuance o |
|
| January 24, 2018 |
BARBARA K. CEGAVSKE Secretary of State 206 North Carson Street Carson City, Nevada 89701-4299 (775) 684 5708 Website: secretaryofstate.biz Certificate of Change Pursuant to NRS 78.209 Filed in the office of Ross Miller Secretary of State State of Nevada Document Number 20130611367-60 Filing Date and Time 09/17/2013 11:43 AM Entity Number E0385202010-4 ABOVE SPACE IS FOR OFFICE USE ONLY USE BLACK I |
|
| January 24, 2018 |
Amendment to Articles of Incorporation, dated May 23, 2016 BARBARA K. CEGAVSKE Secretary of State 206 North Carson Street Carson City, Nevada 89701-4299 (775) 684 5708 Website: secretaryofstate.biz Certificate of Amendment (PURSUANT TO NRS 78.385 and 78.390) Filed in the office of Barbara K. Cegavske Secretary of State State of Nevada Document Number 20160232347-40 Filing Date and Time 05/23/2016 4:25 PM Entity Number E0385202010-4 USE BLACK INK ONLY-DO N |
|
| January 23, 2018 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 18, 2018 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| January 19, 2018 |
Securities Purchase Agreement dated January 10, 2018 with GHS Investments, LLC SECURITIES PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (?Agreement?) is made as of the 10th day of January, 2018 by and between Rich Pharmaceuticals, Inc. |
|
| January 19, 2018 |
Promissory Note dated January 10, 2018 in favor of GHS Investments, LLC NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| January 19, 2018 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2018 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| January 5, 2018 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 2, 2018 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiza |
|
| December 29, 2017 |
RCHA / Rich Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2017 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number:000-54767 Rich Pharmaceuticals, Inc. |
|
| December 6, 2017 |
RCHA / Rich Pharmaceuticals, Inc. 10-Q (Quarterly Report) 10-Q 1 rcha10q63017.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2017 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number: 000-54767 Rich P |
|
| December 4, 2017 |
Ben Chang Employment Extension 2017 Dear Ben Chang, Rich Pharmaceuticals would like to extend your employment which ended September 6, 2017. |
|
| December 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| November 16, 2017 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| November 16, 2017 |
Securities Purchase Agreement dated November 3, 2017 with GHS Investments, LLC SECURITIES PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (?Agreement?) is made as of the 3rd day of November, 2017 by and between Rich Pharmaceuticals, Inc. |
|
| November 16, 2017 |
Promissory Note dated November 3, 2017 in favor of GHS Investments, LLC NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| November 13, 2017 |
RCHA / Rich Pharmaceuticals, Inc. NT 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54767 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: September 30, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ |
|
| November 6, 2017 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| October 20, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| October 4, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 3, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiza |
|
| September 26, 2017 |
Unregistered Sales of Equity Securities 8-K 1 rcha8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of i |
|
| September 18, 2017 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 5, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organi |
|
| September 18, 2017 |
Letter regarding change in certifying accountant September 14, 2017 Securities and Exchange Commission 450 Fifth Street N.W. Washington, DC 20549 We have read the statements of Rich Pharmaceuticals, Inc., pertaining to our firm included under Item 4.01 of Form 8-K dated September 5, 2017 and agree with such statements as they pertain to our firm. Sincerely, /s/ KLJ & Associates, LLP |
|
| September 13, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 9, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organi |
|
| September 5, 2017 |
RCHA / Rich Pharmaceuticals, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-54146 RICH PHARMACEUTICALS, INC. (Exact name of re |
|
| August 31, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiza |
|
| August 23, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 16, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiza |
|
| August 14, 2017 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54767 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Tra |
|
| August 14, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| August 7, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| July 28, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 20, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| July 21, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 13, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| July 12, 2017 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| July 12, 2017 |
Support and Collaboration Agreement dated July 11, 2017 with Mega Bridge, Inc. SUPPORT AND COLLABORATION AGREEMENT This Support and Collaboration Agreement (the ?Agreement?) is effective as of July 11, 2017 ("Effective Date") by and between Rich Pharmaceuticals, Inc. |
|
| July 12, 2017 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 22, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| July 7, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 22, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| June 30, 2017 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 0001504389 Notification of Late Filing (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: March 31, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] T |
|
| June 23, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| May 30, 2017 |
2017 Stock Option/Stock Issuance Plan RICH PHARMACEUTICALS, INC. 2017 STOCK OPTION/STOCK ISSUANCE PLAN Article One GENERAL PROVISIONS I. PURPOSE OF THE PLAN This 2017 Stock Option/Stock Issuance Plan is intended to promote the interests of Rich Pharmaceuticals, Inc., a Nevada corporation (the ?Corporation?), by providing eligible persons with the opportunity to acquire a proprietary interest, or otherwise increase their proprietary in |
|
| May 30, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorpor |
|
| May 4, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| April 27, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 18, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| April 25, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 18, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| April 25, 2017 |
April 25, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 24, 2017 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 18, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| April 24, 2017 |
Promissory Note dated April 18, 2017 in favor of GHS Investments, LLC NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| April 24, 2017 |
Securities Purchase Agreement dated April 18, 2017 with GHS Investments, LLC SECURITIES PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (?Agreement?) is made as of the 18th day of April, 2017 by and between Rich Pharmaceuticals, Inc. |
|
| April 19, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| April 14, 2017 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 5, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| April 14, 2017 |
As filed with the Securities and Exchange Commission on April 13, 2017 Registration No. |
|
| April 14, 2017 |
Amendment to Articles of Incorporation* BARBARA K. CEGAVSKE Secretary of State 206 North Carson Street Carson City, Nevada 89701-4299 (775) 684 5708 Website: secretaryofstate.biz Certificate of Amendment (PURSUANT TO NRS 78.385 and 78.390) USE BLACK INK ONLY-DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Articles of Incorporation For Nevada Corporations (Pursuant to NRS 78.385 and 78.390?After Issuance o |
|
| April 4, 2017 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| April 4, 2017 |
2017 Stock Option/Stock Issuance Plan RICH PHARMACEUTICALS, INC. 2017 STOCK OPTION/STOCK ISSUANCE PLAN Article One GENERAL PROVISIONS I. PURPOSE OF THE PLAN This 2017 Stock Option/Stock Issuance Plan is intended to promote the interests of Rich Pharmaceuticals, Inc., a Nevada corporation (the “Corporation”), by providing eligible persons with the opportunity to acquire a proprietary interest, or otherwise increase their proprietary in |
|
| April 4, 2017 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| March 28, 2017 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| March 21, 2017 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| March 21, 2017 |
Collaboration Agreement dated March 20, 2017 with I Tech Health Corp COLLABORATION AGREEMENT This Collaboration Agreement ("Agreement") is entered into effective as of March 20, 2017 (the "Effective Date") by and between Rich Pharmaceuticals, Inc, a Nevada corporation ("RPI"), and I Tech Health Corp. |
|
| March 17, 2017 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incor |
|
| March 16, 2017 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| March 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] Preliminary Information Statement [X] Definitive Information Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Rich Pharmaceuticals, Inc. (Name of Registra |
|
| March 2, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Definitive Information Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Rich Pharmaceuticals, Inc. (Name of Registra |
|
| March 2, 2017 |
RICH PHARMACEUTICALS, INC. 9595 Wilshire Blvd, Suite 900 Beverly Hills, CA 90212 Tel. (424) 230-7001 March 1, 2017 VIA EDGAR United States Securities and Exchange Commission Attn: Chris Edwards 100 F Street, N.E. Mailstop 3561 Washington D.C., 20549-7010 RE: Rich Pharmaceuticals, Inc. Preliminary Information Statement on Schedule 14C Filed February 22, 2017 File No. 000-54767 Dear Mr. Edwards, Ric |
|
| March 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Definitive Information Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Rich Pharmaceuticals, Inc. (Name of Registra |
|
| March 1, 2017 |
RICH PHARMACEUTICALS, INC. 9595 Wilshire Blvd, Suite 900 Beverly Hills, CA 90212 Tel. (424) 230-7001 March 1, 2017 VIA EDGAR United States Securities and Exchange Commission Attn: Chris Edwards 100 F Street, N.E. Mailstop 3561 Washington D.C., 20549-7010 RE: Rich Pharmaceuticals, Inc. Preliminary Information Statement on Schedule 14C Filed February 22, 2017 File No. 000-54767 Dear Mr. Edwards, Ric |
|
| February 27, 2017 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organi |
|
| February 27, 2017 |
Promissory Note in the amount of $20,000 dated February 22, 2017 with GHS Investments, LLC PROMISSORY NOTE Principal Amount: $20,000.00 Date: February 21, 2017 FOR VALUE RECEIVED, Rich Pharmaceuticals, Inc., a Nevada corporation ("Company"), promises to pay of GHS Investments, LLC, a Nevada Limited Liability Company ("Holder"), or order, at Holder's place of business, the principal amount of $20,000.00, with interest on such amount until paid, at the rate set forth below and payable pur |
|
| February 27, 2017 |
Debt Purchase Agreement dated February 17, 2017 with GHS Investments, LLC DEBT PURCHASE AGREEMENT This Debt Purchase Agreement (the “Agreement”) made as of this 17th day of February, 2017 by and between LG Capital Funding, LLC (the “Seller”) and GHS Investments, LLC (the “Buyer”). |
|
| February 27, 2017 |
Registration Rights Agreement dated February 22, 2017 with GHS Investments, LLC REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the ?Agreement?), dated as of February 22, 2017 (the ?Execution Date?), is entered into by and between Rich Pharmaceuticals, Inc. |
|
| February 27, 2017 |
Equity Financing Agreement dated February 22, 2017 with GHS Investments, LLC EQUITY FINANCING AGREEMENT This EQUITY FINANCING AGREEMENT (the ?Agreement?), dated as of February 22, 2017 (the ?Execution Date?), is entered into by and between Rich Pharmaceuticals, Inc. |
|
| February 27, 2017 |
Promissory Note in the amount of $563,027 dated February 17, 2017 in favor of GHS Investments, LLC NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| February 27, 2017 |
Promissory Note in the amount of $20,899.89 dated February 22, 2017 with GHS Investments, LLC PROMISSORY NOTE Principal Amount: $20,000.00 Date: February 21, 2017 FOR VALUE RECEIVED, Rich Pharmaceuticals, Inc., a Nevada corporation ("Company"), promises to pay of GHS Investments, LLC, a Nevada Limited Liability Company ("Holder"), or order, at Holder's place of business, the principal amount of $20,000.00, with interest on such amount until paid, at the rate set forth below and payable pur |
|
| February 27, 2017 |
Promissory Note in the amount of $15,000 dated February 22, 2017 with GHS Investments, LLC NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| February 27, 2017 |
Promissory Note in the amount of $59,799.12 dated February 22, 2017 with GHS Investments, LLC NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| February 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Definitive Information Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Rich Pharmaceuticals, Inc. (Name of Registra |
|
| February 13, 2017 |
Rich Pharmaceuticals 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2016 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number: 000-54767 Rich Pharmaceuticals, Inc. |
|
| January 19, 2017 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| January 12, 2017 |
Schedule 13G/A No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Rich Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76303T308 (CUSIP Number) January 10, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 11, 2017 |
Promissory Note dated January 5, 2017 in favor of GHS Investments, LLC NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| January 11, 2017 |
Securities Purchase Agreement dated January 5, 2017 with GHS Investments, LLC EX-10.56 2 ex1056.htm EX-10.56 SECURITIES PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (“Agreement”) is made as of the 5th day of January, 2017 by and between Rich Pharmaceuticals, Inc., (the “Company”), and GHS Investments, LLC (the “Investor”). Recitals A. The Investor wishes to purchase from the Company and the Company wishes to sell and issue to the Investor, upon the terms and conditions stated |
|
| January 11, 2017 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2017 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiza |
|
| December 16, 2016 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organi |
|
| November 30, 2016 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organi |
|
| November 21, 2016 |
Rich Pharmaceuticals 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2016 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number:000-54767 Rich Pharmaceuticals, Inc. |
|
| November 15, 2016 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| November 14, 2016 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54767 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: September 30, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ |
|
| November 4, 2016 |
8% Convertible Redeemable Promissory Note dated October 20, 2016 with LG Capital Funding, LLC THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT?) US $32,000. |
|
| November 4, 2016 |
Confession of Judgement dated October 20, 2016 SUPREME COURT OF THE STATE OF NEW YORK COUNTY OF KINGS LG CAPITAL FUNDING, LLC Plaintiff, v. |
|
| November 4, 2016 |
Securities Purchase Agreement dated October 20, 2016 with LG Capital Funding, LLC SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of October 20, 2016, by and between Rich Pharmaceuticals, Inc. |
|
| November 4, 2016 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 28, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| October 31, 2016 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| October 31, 2016 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organ |
|
| October 31, 2016 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organ |
|
| October 31, 2016 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 26, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organ |
|
| September 10, 2016 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiza |
|
| August 22, 2016 |
Rich Pharmaceuticals 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number:000-54767 Rich Pharmaceuticals, Inc. |
|
| August 22, 2016 |
Rich Pharmaceuticals 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number:000-54767 Rich Pharmaceuticals, Inc. |
|
| August 22, 2016 |
Rich Pharmaceuticals 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2016 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-54146 RICH PHARMACEUTICALS, INC. (Exact name of re |
|
| August 22, 2016 |
Rich Pharmaceuticals 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2016 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-54146 RICH PHARMACEUTICALS, INC. (Exact name of re |
|
| August 15, 2016 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54767 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Tra |
|
| August 15, 2016 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54767 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Tra |
|
| June 29, 2016 |
8% Convertible Redeemable Promissory Note dated June 23, 2016 with LG Capital Funding, LLC THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT?) US $56,000. |
|
| June 29, 2016 |
Collateralized Secured Promissory Note dated June 23, 2016 issued by LG Capital Funding, LLC THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. |
|
| June 29, 2016 |
8% Convertible Redeemable Promissory Note dated June 23, 2016 with LG Capital Funding, LLC THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT?) US $56,000. |
|
| June 29, 2016 |
Securities Purchase Agreement dated June 23, 2016 with LG Capital Funding, LLC SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of June 23, 2016, by and between Rich Pharmaceuticals, Inc. |
|
| June 29, 2016 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 25, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| June 29, 2016 |
Confession of Judgement dated June 23, 2016 EX-10.52 6 ex1052.htm EX-10.52 SUPREME COURT OF THE STATE OF NEW YORK COUNTY OF KINGS LG CAPITAL FUNDING, LLC Plaintiff, v. RICH PHARMACEUTICALS, INC. Defendant. Index No.: AFFIDAVIT OF CONFESSION OF JUDGMENT STATE OF NEW YORK ) ) SS: COUNTY OF NEW YORK) Ben Cheng, being duly sworn, deposes and states: 1. I am the CEO of Rich Pharmaceuticals, Inc. (“RCHA” or “Defendant”), a non-resident, Nevada Co |
|
| June 28, 2016 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 0001504389 Notification of Late Filing (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: March 31, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] T |
|
| June 24, 2016 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| June 15, 2016 |
8% Convertible Redeemable Promissory Note dated June 8, 2016 with LG Capital Funding, LLC THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT?) US $84,250. |
|
| June 15, 2016 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 9, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizatio |
|
| June 15, 2016 |
Securities Purchase Agreement dated June 8, 2016 with LG Capital Funding, LLC SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of June 8, 2016, by and between Rich Pharmaceuticals, Inc. |
|
| June 15, 2016 |
8% Convertible Redeemable Promissory Note dated June 8, 2016 with LG Capital Funding, LLC THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT?) US $84,250. |
|
| June 15, 2016 |
Collateralized Secured Promissory Note dated June 8, 2016 issued by LG Capital Funding, LLC THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. |
|
| June 13, 2016 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizatio |
|
| June 13, 2016 |
Secured Promissory Note dated May 31, 2016 with Computerlaw Group, LLP SECURED PROMISSORY NOTE $900,000.00 May 31, 2016 FOR VALUE RECEIVED, each of the undersigned parties, jointly, severally, individually and collectively (collectively the ?Company?), hereby promises to pay to the order of COMPUTERLAW GROUP LLP, a limited liability law partnership of the State of California (?Payee?; Payee and any subsequent holders hereof are hereinafter referred to collectively as |
|
| June 6, 2016 |
RCHA / Rich Pharmaceuticals, Inc. / LG CAPITAL FUNDING, LLC - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Rich Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76303T308 (CUSIP Number) June 2, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| April 18, 2016 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| March 29, 2016 |
Rich Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 22, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| March 18, 2016 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 9, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| March 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] Preliminary Information Statement [X] Definitive Information Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Rich Pharmaceuticals, Inc. (Name of Registra |
|
| March 9, 2016 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organi |
|
| March 3, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Definitive Information Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Rich Pharmaceuticals, Inc. (Name of Registra |
|
| February 26, 2016 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organi |
|
| February 22, 2016 |
Rich Pharmaceuticals 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2015 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number:000-54767 Rich Pharmaceuticals, Inc. |
|
| February 16, 2016 |
NT 10-Q 1 mainbody.htm MAINBODY U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54767 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2015 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Tr |
|
| February 12, 2016 |
BARBARA K. CEGAVSKE Secretary of State 206 North Carson Street Carson City, Nevada 89701-4299 (775) 684 5708 Website: secretaryofstate.biz Certificate of Change Pursuant to NRS 78.209 USE BLACK INK ONLY ? DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Change filed Pursuant to NRS 78.209 For Nevada Profit Corporations 1. Name of corporation: Rich Pharmaceuticals, Inc. 2. The boa |
|
| February 12, 2016 |
Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Amendment #1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorpora |
|
| February 12, 2016 |
Rich Pharmaceuticals, Inc. Announces Reverse Split Rich Pharmaceuticals, Inc. Announces Reverse Split February 10, 2015 Beverly Hills, California?Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" or the ?Company") today announced a 1-for-100 reverse split of its issued and outstanding shares of common stock effective at the opening of trading on Thursday, February 11, 2015. The Company?s common stock will trade on a split-adju |
|
| February 11, 2016 |
Rich Pharmaceuticals RCHA8K02082015 (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| February 11, 2016 |
BARBARA K. CEGAVSKE Secretary of State 206 North Carson Street Carson City, Nevada 89701-4299 (775) 684 5708 Website: secretaryofstate.biz Certificate of Change Pursuant to NRS 78.209 USE BLACK INK ONLY ? DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Change filed Pursuant to NRS 78.209 For Nevada Profit Corporations 1. Name of corporation: Rich Pharmaceuticals, Inc. 2. The boa |
|
| February 11, 2016 |
Rich Pharmaceuticals, Inc. Announces Reverse Split Rich Pharmaceuticals, Inc. Announces Reverse Split February 10, 2015 Beverly Hills, California?Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" or the ?Company") today announced a 1-for-100 reverse split of its issued and outstanding shares of common stock effective at the opening of trading on Thursday, February 11, 2015. The Company?s common stock will trade on a split-adju |
|
| February 5, 2016 |
RCHA / Rich Pharmaceuticals, Inc. / Toledo Advisors LLC Passive Investment SC 13G/A 1 fp0017857sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* Rich Pharmaceuticals Inc. (Name of Issuer) COMMON STOCK $0.001 PER SHARE PAR VALUE (Title of Class of Securities) 76303T20 |
|
| January 12, 2016 |
Rich Pharmaceuticals RCHA8K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2016 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiza |
|
| January 6, 2016 |
RCHA / Rich Pharmaceuticals, Inc. / Typenex Co-Investment, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Rich Pharmaceuticals, Inc. (Name of Issuer) Common stock, $.001 par value (Title of Class of Securities) 76303T209 (CUSIP Number) Calendar Year 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 4, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiza |
|
| December 31, 2015 |
Rich Pharmaceuticals RCHA8K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| December 24, 2015 |
As Filed with the Securities and Exchange Commission on December 24, 2015 Registration No. |
|
| December 21, 2015 |
RICH PHARMACUETICALS, INC. 2013 EQUITY INCENTIVE PLAN AMENDMENT NO. 3 December 15, 2015 WHEREAS, Rich Pharmaceuticals, Inc., a Nevada corporation (the "Corporation"), has adopted the 2013 Equity Incentive Plan (the ?2013 Plan?) and reserved 60,004,800 shares of the Corporation's common stock (the "Shares") under the 2013 Plan; WHEREAS, on October 6, 2014, pursuant to the terms of the Plan, the Boa |
|
| December 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organi |
|
| December 7, 2015 |
Rich Pharmaceuticals MAINBODY (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 23, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organi |
|
| November 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number:000-54767 Rich Pharmaceuticals, Inc. |
|
| November 13, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54767 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: September 30, 2015 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ |
|
| November 10, 2015 |
Rich Pharmaceuticals MAINBODY (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| October 14, 2015 |
625,000,000 Shares of Common Stock PROSPECTUS SUPPLEMENT NO.2 To Prospectus dated June 11, 2015 Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-204358 625,000,000 Shares of Common Stock This prospectus relates to the resale of up to 625,000,000 shares of common stock of Rich Pharmaceuticals, Inc. (?we? or the ?Company?), par value $0.001 per share, issuable to LG Capital Funding, LLC (?LG?) pursuant to that amended |
|
| October 13, 2015 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 7, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiza |
|
| October 7, 2015 |
As filed with the Securities and Exchange Commission on October 7, 2015 Registration No. |
|
| September 25, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2015 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number:000-54767 Rich Pharmaceuticals, Inc. |
|
| September 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2015 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-54146 RICH PHARMACEUTICALS, INC. (Exact name of re |
|
| September 17, 2015 |
POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned, being a director or officer, or both, of Rich Pharmaceuticals, Inc. |
|
| September 17, 2015 |
List of Subsidiaries None. |
|
| September 11, 2015 |
RCHA / Rich Pharmaceuticals, Inc. / VIS VIRES GROUP, INC. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. )* RICH PHARMACEUTICALS, INC. (Name of issuer) Common Stock, $0.001 value per share (Title of class of securities) 76303T209 (CUSIP number) September 8, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| August 14, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54767 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2015 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Tra |
|
| August 10, 2015 |
Rich Pharmaceuticals MAINBODY (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| August 10, 2015 |
Employment Agreement, dated August 4, 2015 with Richard Salvador EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of Aug 4, 2015 by and between Rich Pharmaceuticals, Inc. |
|
| June 29, 2015 |
625,000,000 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated June 11, 2015 Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-204358 625,000,000 Shares of Common Stock This prospectus relates to the resale of up to 625,000,000 shares of common stock of Rich Pharmaceuticals, Inc. (?we? or the ?Company?), par value $0.001 per share, issuable to LG Capital Funding, LLC (?LG?) pursuant to that amended |
|
| June 29, 2015 |
Rich Pharmaceuticals MAINBODY (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 22, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| June 29, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 0001504389 Notification of Late Filing (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: March 31, 2015 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] T |
|
| June 18, 2015 |
As Filed with the Securities and Exchange Commission on June 18, 2015 Registration No. |
|
| June 17, 2015 |
June 17, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 17, 2015 |
Unregistered Sales of Equity Securities 8-K 1 mainbody.htm MAINBODY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of |
|
| June 11, 2015 |
As filed with the Securities and Exchange Commission on June 11, 2015 Registration No. |
|
| June 11, 2015 |
Amended and Restated Investment Agreement dated June 10, 2015 with LG Capital Funding, LLC (19) AMENDED AND RESTATED INVESTMENT AGREEMENT This AMENDED AND RESTATED INVESTMENT AGREEMENT (the “Agreement”), dated as of June, 10, 2015 (the “Execution Date”), is entered into by and between Rich Pharmaceuticals, Inc. |
|
| June 2, 2015 |
Security Agreement dated May 27, 2015 with Typenex Co-Investment, LLC Security Agreement This Security Agreement (this ?Agreement?), dated as of May 27, 2015, is executed by Rich Pharmaceuticals, Inc. |
|
| June 2, 2015 |
Secured Convertible Promissory Note dated May 27, 2015 with Typenex Co-Investment, LLC SECURED CONVERTIBLE PROMISSORY NOTE Effective Date: May 27, 2015 U.S. $362,500.00 FOR VALUE RECEIVED, Rich Pharmaceuticals, Inc., a Nevada corporation (?Borrower?), promises to pay to Typenex Co-Investment, LLC, a Utah limited liability company, or its successors or assigns (?Lender?), $362,500.00 and any interest, fees, charges, and late fees on the date that is twelve (12) months after the Purch |
|
| June 2, 2015 |
Rich Pharmaceuticals MAINBODY (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| June 2, 2015 |
Securities Purchase Agreement dated May 27, 2015 with Typenex Co-Investment, LLC Securities Purchase Agreement This Securities Purchase Agreement (this ?Agreement?), dated as of May 27, 2015, is entered into by and between Rich Pharmaceuticals, Inc. |
|
| June 2, 2015 |
THIS NOTE MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE ALIENATED OR ENCUMBERED WITHOUT THE PRIOR WRITTEN CONSENT OF INVESTOR. |
|
| May 21, 2015 |
Investment Agreement dated May 19, 2015 with LG Capital Funding , LLC* INVESTMENT AGREEMENT This INVESTMENT AGREEMENT (the "Agreement"), dated as of May 19, 201 5 (the "Execution Date"), is entered into by and between Rich Pharmaceuticals, Inc. |
|
| May 21, 2015 |
As filed with the Securities and Exchange Commission on May 21, 2015 Registration No. |
|
| May 12, 2015 |
Collateralized Secured Promissory Note with LG Capital Funding dated May 5, 2015 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. |
|
| May 12, 2015 |
Convertible Promissory Note with Vis Veres Group, Inc. dated May 6, 2015 EX-10.37 6 ex1037.htm EX1037 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATIO |
|
| May 12, 2015 |
Back-End Convertible Promissory Note with LG Capital Funding dated May 5, 2015 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT?) US $68,900. |
|
| May 12, 2015 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organization |
|
| May 12, 2015 |
Convertible Promissory Note with LG Capital Funding dated May 5, 2015 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT?) US $68,900. |
|
| May 12, 2015 |
Securities Purchase Agreement with LG Capital Funding dated May 5, 2015 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of May 5, 2015, by and between Rich Pharmaceuticals, Inc. |
|
| April 14, 2015 |
Rich Pharmaceuticals MAINBODY (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| April 8, 2015 |
RICH PHARMACUETICALS, INC. 2013 EQUITY INCENTIVE PLAN AMENDMENT NO. 2 April 6, 2015 WHEREAS, Rich Pharmaceuticals, Inc., a Nevada corporation (the "Corporation"), has adopted the 2013 Equity Incentive Plan (the ?2013 Plan?) and reserved 60,004,800 shares of the Corporation's common stock (the "Shares") under the 2013 Plan; WHEREAS, on October 6, 2014, pursuant to the terms of the Plan, the Board o |
|
| April 8, 2015 |
Rich Pharmaceuticals MAINBODY (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 6, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| April 3, 2015 |
Securities Purchase Agreement dated March 26, 2015 with Adar Bays, LLC SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of March 26, 2015, by and between RICH PHARMACEUTICALS, INC. |
|
| April 3, 2015 |
Convertible Promissory Note dated March 26, 2015 with Adar Bays, LLC THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT?) US $29,680. |
|
| April 3, 2015 |
Rich Pharmaceuticals MAINBODY (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 26, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| April 3, 2015 |
Adar Bays, LLC Collateralized Secured Promissory Note dated March 26, 2015 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. |
|
| April 3, 2015 |
Back-End Convertible Promissory Note with Adar Bays, LLC THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT?) US $29,680. |
|
| March 16, 2015 |
Convertible Promissory Note dated March 9, 2015 with Auctus Private Equity Fund, LLC NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| March 16, 2015 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizat |
|
| March 16, 2015 |
Securities Purchase Agreement dated March 9, 2015 with Auctus Private Equity Fund, LLC SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of March 9, 2015, by and between RICH PHARMACEUTICALS, INC. |
|
| March 6, 2015 |
Rich Pharmaceuticals MAINBODY (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organizati |
|
| March 2, 2015 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or orga |
|
| February 25, 2015 |
Convertible Promissory Note dated February 5, 2015 issued to KBM Worldwide, Inc. NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| February 25, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment #1 [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2014 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number:000-54767 Rich Pharmaceuticals, Inc. |
|
| February 24, 2015 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organi |
|
| February 23, 2015 |
RCHA / Rich Pharmaceuticals, Inc. / Vista Capital Investments, LLC - SCHEDULE 13G Passive Investment SC 13G 1 sc13g022015sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Rich Pharmaceuticals, Inc. (Name of issuer) Common Stock, $0.001 value per share (Title of class of securities) 76303T209 (CUSIP number) February 11, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 23, 2015 |
Convertible Promissory Note dated February 5, 2015 issued to KBM Worldwide, Inc. NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| February 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2014 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number:000-54767 Rich Pharmaceuticals, Inc. |
|
| February 18, 2015 |
RCHA / Rich Pharmaceuticals, Inc. / LG CAPITAL FUNDING, LLC - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Rich Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76303T209 (CUSIP Number) February 17, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 18, 2015 |
RCHA / Rich Pharmaceuticals, Inc. / Toledo Advisors LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Rich Pharmaceuticals Inc. (Name of Issuer) COMMON STOCK $0.001 PER SHARE PAR VALUE (Title of Class of Securities) 76303T209 (CUSIP Number) F |
|
| February 17, 2015 |
RCHA / Rich Pharmaceuticals, Inc. NT 10-Q - - MAINBODY U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54767 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] |
|
| January 15, 2015 |
Convertible Promissory Note dated January 9, 2015 with KBM Worldwide, Inc. NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| January 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 12, 2015 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| December 2, 2014 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2014 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| December 2, 2014 |
Convertible Promissory Note dated November 25, 2014 with KBM Worldwide, Inc. EX-10.24 2 ex1024.htm EXHIBIT 10.24 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGI |
|
| November 19, 2014 |
Convertible Promissory Note dated October 6, 3014 issued to KBM Worldwide, Inc NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| November 19, 2014 |
Convertible Promissory Note dated October 6, 3014 issued to KBM Worldwide, Inc NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| November 19, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2014 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number:000-54767 Rich Pharmaceuticals, Inc. |
|
| November 19, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2014 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period to Commission File Number:000-54767 Rich Pharmaceuticals, Inc. |
|
| November 14, 2014 |
Convertible Promissory Note dated November 6, 2014 with JSJ Investments, Inc. EX-10.22 2 ex1022.htm EX1022 NEITHER THIS NOTE NOR THE SECURITIES THAT MAY BE ISSUED BY THE BORROWER UPON CONVERSION HEREOF (COLLECTIVELY, THE “SECURITIES”) HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THE SECURITIES NOR ANY INTEREST OR PARTICIPATION THEREIN MAY BE OFFERED FOR SALE, SOLD, TRAN |
|
| November 14, 2014 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2014 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiz |
|
| November 13, 2014 |
RCHA / Rich Pharmaceuticals, Inc. NT 10-Q - - MAINBODY U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54767 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: September 30, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ |
|
| November 10, 2014 |
90,000,000 Shares of Common Stock Amendment No. 1 to Prospectus Supplement No. 1 Filed Pursuant to Rule 424(b)(3) To prospectus dated September 16, 2014 Registration Statement No. 333-198872 90,000,000 Shares of Common Stock This Amendment No. 1 to Prospectus Supplement No. 1 is intended to supersede and replace Prospectus Supplement No. 1 which was filed on November 6, 2014. This Amendment No. 1 to Prospectus Supplement No. 1 mod |
|
| November 6, 2014 |
90,000,000 Shares of Common Stock Prospectus Supplement No. 1 Filed Pursuant to Rule 424(b)(3) To prospectus dated September 16, 2014 Registration Statement No. 333-198872 90,000,000 Shares of Common Stock This prospectus supplement modifies, supersedes and supplements information contained in, and should be read in conjunction with the prospectus, dated September 16, 2014 related to the resale of up to 90,000,000 shares of common |
|
| October 8, 2014 |
Assignment Agreement dated October 6, 2014 ASSIGNMENT AGREEMENT This ASSIGNMENT AGREEMENT (“Agreement”) is entered into as of October 6, 2014 (the “Effective Date”) by and between Rich Pharmaceuticals, Inc. |
|
| October 8, 2014 |
2013 Plan Amendment dated October 6, 2014 RICH PHARMACUETICALS, INC. 2013 EQUITY INCENTIVE PLAN AMENDMENT October 6, 2014 WHEREAS, Rich Pharmaceuticals, Inc., a Nevada corporation (the "Corporation"), has adopted the 2013 Equity Incentive Plan (the “2013 Plan”) and reserved 60,004,800 shares of the Corporation's common stock (the "Shares") under the 2013 Plan; WHEREAS, pursuant to the terms of the Plan, the Board of Directors approved an |
|
| October 8, 2014 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 6, 2014 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organiza |
|
| September 25, 2014 |
Master Convertible Promissory Note dated September 18, 2014 with Typenex Co-Investment LLC, LLC MASTER CONVERTIBLE PROMISSORY NOTE Effective Date: September 18, 2014 U.S. $64,500.00 FOR VALUE RECEIVED, Rich Pharmaceuticals, Inc., a Nevada corporation (“Borrower”), promises to pay to Typenex Co-Investment, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $64,500.00 and any interest, fees, charges and penalties in accordance with the terms set forth herein. This |
|
| September 25, 2014 |
Securities Purchase Agreement dated September 23, 2014 with Auctus Private Equity Fund, LLC SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 23, 2014, by and between RICH PHARMACEUTICALS, INC. |
|
| September 25, 2014 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2014 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEVADA 000-54767 46-3259117 (State or other jurisdiction of incorporation or organ |
|
| September 25, 2014 |
Convertible Promissory Note dated September 23, 2014 with Auctus Private Equity Fund, LLC EX-10.21 4 ex1021.htm EX1021 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATIO |
|
| September 22, 2014 |
RCHA / Rich Pharmaceuticals, Inc. S-1 - Registration Statement - MAINBODY As filed with the Securities and Exchange Commission on , 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RICH PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 2834 46-3259117 (State or other jurisdiction of Incorporation or organization) (Primary S |
|
| August 29, 2014 |
RCHA / Rich Pharmaceuticals, Inc. S-8 - - MAINBODY As Filed with the Securities and Exchange Commission on August 29, 2014 Registration No. |
|
| August 29, 2014 |
Form of Notice of Grant for the 2013 Equity Incentive Plan RICH PHARMACEUTICALS, INC. 2013 STOCK OPTION/STOCK ISSUANCE PLAN NONSTATUTORY STOCK OPTION AGREEMENT Rich Pharmaceuticals, Inc., a Nevada corporation (the "Company"), hereby grants an Option to purchase shares of its common stock (the "Shares") to the Optionee named below. The terms and conditions of the Option are set forth in this cover sheet, in the attachment and in the Rich Pharmaceuticals, I |
|
| August 29, 2014 |
Rich Pharmaceuticals, Inc. 2013 Equity Incentive Plan RICH PHARMACEUTICALS, INC. 2013 STOCK OPTION/STOCK ISSUANCE PLAN Article One GENERAL PROVISIONS I. PURPOSE OF THE PLAN This 2013 Stock Option/Stock Issuance Plan is intended to promote the interests of Rich Pharmaceuticals, Inc., a Nevada corporation (the “Corporation”), by providing eligible persons with the opportunity to acquire a proprietary interest, or otherwise increase their proprietary in |
